JUBLPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.5
| Stock Code | JUBLPHARMA | Market Cap | 15,747 Cr. | Current Price | 989 ₹ | High / Low | 1,250 ₹ |
| Stock P/E | 502 | Book Value | 145 ₹ | Dividend Yield | 0.50 % | ROCE | 1.80 % |
| ROE | 1.35 % | Face Value | 1.00 ₹ | DMA 50 | 950 ₹ | DMA 200 | 982 ₹ |
| Chg in FII Hold | -0.06 % | Chg in DII Hold | 0.40 % | PAT Qtr | 65.7 Cr. | PAT Prev Qtr | 6.60 Cr. |
| RSI | 58.1 | MACD | 22.3 | Volume | 64,118 | Avg Vol 1Wk | 2,43,535 |
| Low price | 784 ₹ | High price | 1,250 ₹ | PEG Ratio | -35.4 | Debt to equity | 0.02 |
| 52w Index | 43.9 % | Qtr Profit Var | 7,200 % | EPS | 3.97 ₹ | Industry PE | 31.6 |
📈 Optimal Buy Price: 975 – 995 ₹
💰 Profit-Taking Levels: 1,020 ₹ / 1,050 ₹
🛑 Stop-Loss Zone: 960 ₹
⏳ Exit Guidance: If already holding, consider exiting near 1,020–1,030 ₹ if momentum slows. Exit below 960 ₹ if bearish volume spikes or RSI dips under 55.
✅ Positive
- Price trading above DMA 50 (950 ₹) and DMA 200 (982 ₹), confirming short-term strength.
- RSI at 58.1 indicates moderate bullish momentum.
- MACD at 22.3 shows strong bullish crossover.
- Quarterly PAT surged (₹6.6 Cr → ₹65.7 Cr), showing earnings recovery.
- DII holdings increased (+0.40%), reflecting domestic institutional support.
- Debt-to-equity ratio at 0.02 indicates negligible leverage risk.
⚠️ Limitation
- Extremely high P/E (502) vs industry PE (31.6) suggests severe overvaluation.
- ROCE (1.80%) and ROE (1.35%) are very weak, limiting efficiency.
- EPS at 3.97 ₹ is modest compared to valuation.
- Volume (64k) far below weekly average (2.43 lakh), limiting intraday participation.
- PEG ratio at -35.4 indicates poor valuation relative to growth.
📉 Company Negative News
- FII holdings decreased (-0.06%), showing reduced foreign investor confidence.
- Weak profitability metrics despite PAT recovery.
📊 Company Positive News
- Sequential PAT turnaround from ₹6.6 Cr to ₹65.7 Cr.
- DII inflows (+0.40%) show domestic support.
- Strong 52-week performance at 43.9% highlights investor confidence.
🏭 Industry
- Industry PE at 31.6 vs JUBLPHARMA’s 502, suggesting extreme premium valuation.
- Pharma sector remains resilient with demand growth, though margins are under pressure.
📌 Conclusion
JUBLPHARMA shows moderate intraday potential with bullish RSI/MACD and PAT recovery, but extreme valuation, weak fundamentals, and low volume limit upside. Entry near 975–995 ₹ with exits around 1,020–1,050 ₹ is suitable for cautious trades. Strict stop-loss at 960 ₹ is essential due to volatility and overvaluation risks.
Would you like me to extend this into a pharma sector peer comparison to evaluate how JUBLPHARMA stacks up against competitors, or prepare a swing trade analysis for medium-term positioning?